The Clinical and Economic Burden of Idiopathic Hypersomnia: Results from the Real-World Idiopathic Hypersomnia Total Health Model (RHYTHM) Study.

IF 3.4 2区 医学 Q2 CLINICAL NEUROLOGY
Nature and Science of Sleep Pub Date : 2025-07-30 eCollection Date: 2025-01-01 DOI:10.2147/NSS.S498432
Ragy Saad, Sarah C Markt, Prasheel Lillaney, Deb A Profant, Douglas S Fuller, Elizabeth M Poole, Trevor Alvord, Patricia Prince, Shaina Desai, Marisa Whalen, Weiyi Ni, Jed Black
{"title":"The Clinical and Economic Burden of Idiopathic Hypersomnia: Results from the Real-World Idiopathic Hypersomnia Total Health Model (RHYTHM) Study.","authors":"Ragy Saad, Sarah C Markt, Prasheel Lillaney, Deb A Profant, Douglas S Fuller, Elizabeth M Poole, Trevor Alvord, Patricia Prince, Shaina Desai, Marisa Whalen, Weiyi Ni, Jed Black","doi":"10.2147/NSS.S498432","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Limited research describes the clinical and economic burden of idiopathic hypersomnia. This study compared this burden in individuals with idiopathic hypersomnia against matched controls.</p><p><strong>Patients and methods: </strong>This retrospective cohort study analyzed Merative™ MarketScan<sup>®</sup> US claims (12/31/2013-2/29/2020). Individuals were ≥18 years of age and continuously enrolled during a 2-year assessment period. Individuals with idiopathic hypersomnia entered the cohort upon their first idiopathic hypersomnia medical claim; they were matched 1:5 with non-idiopathic hypersomnia controls on age, sex, region, insurance type, and cohort entry date. Odds of comorbid conditions experienced by individuals in either cohort during the 2-year assessment were compared. Healthcare resource utilization (HCRU) was presented as percentages by care setting. Median medical cost per patient per year (PPPY) was the sum of inpatient, outpatient, and emergency costs. <i>P</i>-values were not adjusted for multiplicity.</p><p><strong>Results: </strong>This analysis included 11,412 individuals with idiopathic hypersomnia and 57,058 matched controls. In both cohorts, median age was 45 years and 65% of individuals were female. Compared with matched controls, individuals with idiopathic hypersomnia had 1.6- to 4.4-fold higher odds (all <i>P</i><0.0001) of grouped conditions defined by multilevel Clinical Classifications Software categories, from neoplasms to nervous systems diseases, including sleep-related conditions. Individuals with idiopathic hypersomnia had higher odds of all comorbid conditions evaluated, including sleep-related, cardiovascular and cardiometabolic, and neuropsychiatric conditions, compared with matched controls. Individuals with idiopathic hypersomnia had higher HCRU (outpatient, 100% vs 96.1%; emergency department, 46.6% vs 34.3%; inpatient, 10.2% vs 8.5%, all <i>P</i><0.0001) than matched controls. Median medical costs PPPY were higher for individuals with idiopathic hypersomnia ($4854) than matched controls ($1348).</p><p><strong>Conclusion: </strong>Compared with matched controls, individuals with idiopathic hypersomnia had a higher clinical burden, spanning multiple organ systems, and a higher economic burden. Individuals' clinical profiles may be considered when treating idiopathic hypersomnia and providing holistic care.</p>","PeriodicalId":18896,"journal":{"name":"Nature and Science of Sleep","volume":"17 ","pages":"1743-1755"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318847/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature and Science of Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/NSS.S498432","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Limited research describes the clinical and economic burden of idiopathic hypersomnia. This study compared this burden in individuals with idiopathic hypersomnia against matched controls.

Patients and methods: This retrospective cohort study analyzed Merative™ MarketScan® US claims (12/31/2013-2/29/2020). Individuals were ≥18 years of age and continuously enrolled during a 2-year assessment period. Individuals with idiopathic hypersomnia entered the cohort upon their first idiopathic hypersomnia medical claim; they were matched 1:5 with non-idiopathic hypersomnia controls on age, sex, region, insurance type, and cohort entry date. Odds of comorbid conditions experienced by individuals in either cohort during the 2-year assessment were compared. Healthcare resource utilization (HCRU) was presented as percentages by care setting. Median medical cost per patient per year (PPPY) was the sum of inpatient, outpatient, and emergency costs. P-values were not adjusted for multiplicity.

Results: This analysis included 11,412 individuals with idiopathic hypersomnia and 57,058 matched controls. In both cohorts, median age was 45 years and 65% of individuals were female. Compared with matched controls, individuals with idiopathic hypersomnia had 1.6- to 4.4-fold higher odds (all P<0.0001) of grouped conditions defined by multilevel Clinical Classifications Software categories, from neoplasms to nervous systems diseases, including sleep-related conditions. Individuals with idiopathic hypersomnia had higher odds of all comorbid conditions evaluated, including sleep-related, cardiovascular and cardiometabolic, and neuropsychiatric conditions, compared with matched controls. Individuals with idiopathic hypersomnia had higher HCRU (outpatient, 100% vs 96.1%; emergency department, 46.6% vs 34.3%; inpatient, 10.2% vs 8.5%, all P<0.0001) than matched controls. Median medical costs PPPY were higher for individuals with idiopathic hypersomnia ($4854) than matched controls ($1348).

Conclusion: Compared with matched controls, individuals with idiopathic hypersomnia had a higher clinical burden, spanning multiple organ systems, and a higher economic burden. Individuals' clinical profiles may be considered when treating idiopathic hypersomnia and providing holistic care.

Abstract Image

Abstract Image

Abstract Image

特发性嗜睡症的临床和经济负担:来自真实世界特发性嗜睡症总健康模型(RHYTHM)研究的结果
目的:有限的研究描述了特发性嗜睡症的临床和经济负担。这项研究比较了特发性嗜睡症患者与匹配对照组的这种负担。患者和方法:本回顾性队列研究分析了Merative™MarketScan®美国索赔(2013年12月31日- 2020年2月29日)。受试者年龄≥18岁,在2年的评估期内连续入组。患有特发性嗜睡症的个体在他们的第一次特发性嗜睡症医疗索赔时进入队列;在年龄、性别、地区、保险类型和队列入组日期方面,他们与非特发性嗜睡症对照者的比例为1:5。比较两组患者在2年评估期间共病的发生率。医疗资源利用率(HCRU)按护理环境以百分比表示。每位患者每年的医疗费用中位数(PPPY)是住院、门诊和急诊费用的总和。p值未因多重性而调整。结果:该分析包括11,412名特发性嗜睡症患者和57,058名匹配的对照组。在这两个队列中,中位年龄为45岁,65%的个体是女性。与匹配的对照组相比,特发性嗜睡症患者的风险高出1.6- 4.4倍(所有ppp)。结论:与匹配的对照组相比,特发性嗜睡症患者的临床负担更高,跨越多器官系统,经济负担更高。在治疗特发性嗜睡症和提供整体护理时,可考虑个人的临床概况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature and Science of Sleep
Nature and Science of Sleep Neuroscience-Behavioral Neuroscience
CiteScore
5.70
自引率
5.90%
发文量
245
审稿时长
16 weeks
期刊介绍: Nature and Science of Sleep is an international, peer-reviewed, open access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep. Specific topics covered in the journal include: The functions of sleep in humans and other animals Physiological and neurophysiological changes with sleep The genetics of sleep and sleep differences The neurotransmitters, receptors and pathways involved in controlling both sleep and wakefulness Behavioral and pharmacological interventions aimed at improving sleep, and improving wakefulness Sleep changes with development and with age Sleep and reproduction (e.g., changes across the menstrual cycle, with pregnancy and menopause) The science and nature of dreams Sleep disorders Impact of sleep and sleep disorders on health, daytime function and quality of life Sleep problems secondary to clinical disorders Interaction of society with sleep (e.g., consequences of shift work, occupational health, public health) The microbiome and sleep Chronotherapy Impact of circadian rhythms on sleep, physiology, cognition and health Mechanisms controlling circadian rhythms, centrally and peripherally Impact of circadian rhythm disruptions (including night shift work, jet lag and social jet lag) on sleep, physiology, cognition and health Behavioral and pharmacological interventions aimed at reducing adverse effects of circadian-related sleep disruption Assessment of technologies and biomarkers for measuring sleep and/or circadian rhythms Epigenetic markers of sleep or circadian disruption.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信